Influence of dose and route of administration on disposition of metronidazole and its major metabolites.
The influence of dose and route of administration on the kinetics of metronidazole and its major metabolites has been investigated in 8 healthy volunteers given 0.5 and 2.0 g i.v. and p.o. Metronidazole elimination kinetics from plasma could be described by an open two-compartment model. The systemic oral bioavailability of both doses was approximately 1. The total systemic clearance of the intravenous 2.0 g dose was 9% lower than that of the 0.5 g dose (p less than 0.05). There were no significant dose-related differences in volume or rate of distribution. The elimination half-life was similar after the four treatments with metronidazole. The major elimination pathways, renal excretion and hepatic oxidation and glucuronidation, accounted for more than 2/3 of the total systemic clearance. Clearance both by hepatic oxidative metabolism and renal excretion was significantly lower after 2.0 than after 0.5 g i.v., whereas there was no significant difference after the oral doses. The results indicate that a high therapeutic dose of metronidazole may be eliminated at a reduced rate, but this is probably not of clinical importance. No single saturable elimination pathway was identified.
D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D001711:Biotransformation; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006900:Hydroxylation; D007263:Infusions, Parenteral; D007700:Kinetics; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage* / Q000378:metabolism; D010084:Oxidation-Reduction
D008795:Metronidazole